Anouk Schrantee1, Hyke G H Tamminga2, Cheima Bouziane3, Marco A Bottelier4, Esther E Bron5, Henk-Jan M M Mutsaerts3, Aeilko H Zwinderman6, Inge R Groote7, Serge A R B Rombouts8, Ramon J L Lindauer9, Stefan Klein10, Wiro J Niessen11, Brent C Opmeer12, Frits Boer9, Paul J Lucassen13, Susan L Andersen14, Hilde M Geurts15, Liesbeth Reneman1. 1. Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands2Brain Imaging Center, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands3Amsterdam Brain and Cognition, University of Amsterdam, Amsterdam, the Netherlands. 2. Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands4d'Arc (Dutch Autism and Attention-Deficit/Hyperactivity Disorder Research Center), Department of Brain and Cognition, University of Amsterdam, Amsterdam, the Netherlands. 3. Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands2Brain Imaging Center, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 4. Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands5Department of Child and Adolescent Psychiatry, Triversum, Alkmaar, the Netherlands. 5. Biomedical Imaging Group Rotterdam, Department of Medical Informatics, Erasmus Medical Center, Rotterdam, the Netherlands7Biomedical Imaging Group Rotterdam, Department of Radiology, Erasmus MC, Rotterdam, the Netherlands. 6. Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 7. Institute of Psychology, Department of Social Sciences, University of Oslo, Oslo, Norway. 8. Institute of Psychology, Leiden University, Leiden, the Netherlands11Department of Radiology, Leids Universitair Medisch Centrum, Leiden, the Netherlands. 9. Department of Child and Adolescent Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands13De Bascule Academic Center for Child and Adolescent Psychiatry, Amsterdam, the Netherlands. 10. Biomedical Imaging Group Rotterdam, Department of Medical Informatics, Erasmus Medical Center, Rotterdam, the Netherlands. 11. Biomedical Imaging Group Rotterdam, Department of Medical Informatics, Erasmus Medical Center, Rotterdam, the Netherlands14Department of Imaging Physics, Faculty of Applied Sciences, Delft University of Technology, Delft, the Netherlands. 12. Clinical Research Unit, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 13. Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, the Netherlands. 14. Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, Massachusetts. 15. d'Arc (Dutch Autism and Attention-Deficit/Hyperactivity Disorder Research Center), Department of Brain and Cognition, University of Amsterdam, Amsterdam, the Netherlands.
Abstract
IMPORTANCE: Although numerous children receive methylphenidate hydrochloride for the treatment of attention-deficit/hyperactivity disorder (ADHD), little is known about age-dependent and possibly lasting effects of methylphenidate on the human dopaminergic system. OBJECTIVES: To determine whether the effects of methylphenidate on the dopaminergic system are modified by age and to test the hypothesis that methylphenidate treatment of young but not adult patients with ADHD induces lasting effects on the cerebral blood flow response to dopamine challenge, a noninvasive probe for dopamine function. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial (Effects of Psychotropic Drugs on Developing Brain-Methylphenidate) among ADHD referral centers in the greater Amsterdam area in the Netherlands between June 1, 2011, and June 15, 2015. Additional inclusion criteria were male sex, age 10 to 12 years or 23 to 40 years, and stimulant treatment-naive status. INTERVENTIONS: Treatment with either methylphenidate or a matched placebo for 16 weeks. MAIN OUTCOMES AND MEASURES: Change in the cerebral blood flow response to an acute challenge with methylphenidate, noninvasively assessed using pharmacological magnetic resonance imaging, between baseline and 1 week after treatment. Data were analyzed using intent-to-treat analyses. RESULTS: Among 131 individuals screened for eligibility, 99 patients met DSM-IV criteria for ADHD, and 50 participants were randomized to receive methylphenidate and 49 to placebo. Sixteen weeks of methylphenidate treatment increased the cerebral blood flow response to methylphenidate within the thalamus (mean difference, 6.5; 95% CI, 0.4-12.6; P = .04) of children aged 10 to 12 years old but not in adults or in the placebo group. In the striatum, the methylphenidate condition differed significantly from placebo in children but not in adults (mean difference, 7.7; 95% CI, 0.7-14.8; P = .03). CONCLUSIONS AND RELEVANCE: We confirm preclinical data and demonstrate age-dependent effects of methylphenidate treatment on human extracellular dopamine striatal-thalamic circuitry. Given its societal relevance, these data warrant replication in larger groups with longer follow-up. TRIAL REGISTRATION: identifier: NL34509.000.10 and trialregister.nl identifier: NTR3103.
RCT Entities:
IMPORTANCE: Although numerous children receive methylphenidate hydrochloride for the treatment of attention-deficit/hyperactivity disorder (ADHD), little is known about age-dependent and possibly lasting effects of methylphenidate on the human dopaminergic system. OBJECTIVES: To determine whether the effects of methylphenidate on the dopaminergic system are modified by age and to test the hypothesis that methylphenidate treatment of young but not adult patients with ADHD induces lasting effects on the cerebral blood flow response to dopamine challenge, a noninvasive probe for dopamine function. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial (Effects of Psychotropic Drugs on Developing Brain-Methylphenidate) among ADHD referral centers in the greater Amsterdam area in the Netherlands between June 1, 2011, and June 15, 2015. Additional inclusion criteria were male sex, age 10 to 12 years or 23 to 40 years, and stimulant treatment-naive status. INTERVENTIONS: Treatment with either methylphenidate or a matched placebo for 16 weeks. MAIN OUTCOMES AND MEASURES: Change in the cerebral blood flow response to an acute challenge with methylphenidate, noninvasively assessed using pharmacological magnetic resonance imaging, between baseline and 1 week after treatment. Data were analyzed using intent-to-treat analyses. RESULTS: Among 131 individuals screened for eligibility, 99 patients met DSM-IV criteria for ADHD, and 50 participants were randomized to receive methylphenidate and 49 to placebo. Sixteen weeks of methylphenidate treatment increased the cerebral blood flow response to methylphenidate within the thalamus (mean difference, 6.5; 95% CI, 0.4-12.6; P = .04) of children aged 10 to 12 years old but not in adults or in the placebo group. In the striatum, the methylphenidate condition differed significantly from placebo in children but not in adults (mean difference, 7.7; 95% CI, 0.7-14.8; P = .03). CONCLUSIONS AND RELEVANCE: We confirm preclinical data and demonstrate age-dependent effects of methylphenidate treatment on human extracellular dopamine striatal-thalamic circuitry. Given its societal relevance, these data warrant replication in larger groups with longer follow-up. TRIAL REGISTRATION: identifier: NL34509.000.10 and trialregister.nl identifier: NTR3103.
Authors: J N Giedd; J Blumenthal; N O Jeffries; F X Castellanos; H Liu; A Zijdenbos; T Paus; A C Evans; J L Rapoport Journal: Nat Neurosci Date: 1999-10 Impact factor: 24.884
Authors: Nora D Volkow; Gene-Jack Wang; Dardo Tomasi; Scott H Kollins; Tim L Wigal; Jeffrey H Newcorn; Frank W Telang; Joanna S Fowler; Jean Logan; Christopher T Wong; James M Swanson Journal: J Neurosci Date: 2012-01-18 Impact factor: 6.167
Authors: Brooke S G Molina; Stephen P Hinshaw; L Eugene Arnold; James M Swanson; William E Pelham; Lily Hechtman; Betsy Hoza; Jeffery N Epstein; Timothy Wigal; Howard B Abikoff; Laurence L Greenhill; Peter S Jensen; Karen C Wells; Benedetto Vitiello; Robert D Gibbons; Andrea Howard; Patricia R Houck; Kwan Hur; Bo Lu; Sue Marcus Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-02-08 Impact factor: 8.829
Authors: Brooke S G Molina; Stephen P Hinshaw; James M Swanson; L Eugene Arnold; Benedetto Vitiello; Peter S Jensen; Jeffery N Epstein; Betsy Hoza; Lily Hechtman; Howard B Abikoff; Glen R Elliott; Laurence L Greenhill; Jeffrey H Newcorn; Karen C Wells; Timothy Wigal; Robert D Gibbons; Kwan Hur; Patricia R Houck Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-05 Impact factor: 8.829
Authors: Ruth L O'Gorman; Mitul A Mehta; Philip Asherson; Fernando O Zelaya; Keeley J Brookes; Brian K Toone; David C Alsop; Steven C R Williams Journal: Neuroimage Date: 2008-04-20 Impact factor: 6.556
Authors: Edmund J S Sonuga-Barke; Daniel Brandeis; Samuele Cortese; David Daley; Maite Ferrin; Martin Holtmann; Jim Stevenson; Marina Danckaerts; Saskia van der Oord; Manfred Döpfner; Ralf W Dittmann; Emily Simonoff; Alessandro Zuddas; Tobias Banaschewski; Jan Buitelaar; David Coghill; Chris Hollis; Eric Konofal; Michel Lecendreux; Ian C K Wong; Joseph Sergeant Journal: Am J Psychiatry Date: 2013-03 Impact factor: 18.112
Authors: Alexandra Philipsen; Thomas Jans; Erika Graf; Swantje Matthies; Patricia Borel; Michael Colla; Laura Gentschow; Daina Langner; Christian Jacob; Silke Groß-Lesch; Esther Sobanski; Barbara Alm; Martina Schumacher-Stien; Michael Roesler; Wolfgang Retz; Petra Retz-Junginger; Bernhard Kis; Mona Abdel-Hamid; Viola Heinrich; Michael Huss; Catherine Kornmann; Arne Bürger; Evgeniy Perlov; Gabriele Ihorst; Michael Schlander; Mathias Berger; Ludger Tebartz van Elst Journal: JAMA Psychiatry Date: 2015-12 Impact factor: 21.596
Authors: Daniel C Javitt; Cameron S Carter; John H Krystal; Joshua T Kantrowitz; Ragy R Girgis; Lawrence S Kegeles; John D Ragland; Richard J Maddock; Tyler A Lesh; Costin Tanase; Philip R Corlett; Douglas L Rothman; Graeme Mason; Maolin Qiu; James Robinson; William Z Potter; Marlene Carlson; Melanie M Wall; Tse-Hwei Choo; Jack Grinband; Jeffrey A Lieberman Journal: JAMA Psychiatry Date: 2018-01-01 Impact factor: 21.596
Authors: K B Walhovd; I Amlien; A Schrantee; D A Rohani; I Groote; A Bjørnerud; A M Fjell; L Reneman Journal: AJNR Am J Neuroradiol Date: 2020-05 Impact factor: 3.825
Authors: Anouk Schrantee; C Bouziane; E E Bron; S Klein; M A Bottelier; J J S Kooij; S A R B Rombouts; L Reneman Journal: Brain Imaging Behav Date: 2018-04 Impact factor: 3.978